Somewhat Positive News Coverage Somewhat Unlikely to Affect Regulus Therapeutics (RGLS) Share Price
News stories about Regulus Therapeutics (NASDAQ:RGLS) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regulus Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2516166813878 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Express Scripts Holding Company (ESRX) is at $60.32 per share and Regulus Therapeutics Inc. (RGLS) is listed at $1.00 – Stocks Gallery (stocksgallery.com)
- Regulus Therapeutics Inc. (RGLS) : Keep an eye on Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Regulus Therapeutics Inc. (RGLS) Set to Announce Earnings on Tuesday (americanbankingnews.com)
- Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017 (finance.yahoo.com)
- Head-To-Head Survey: Regulus Therapeutics (RGLS) vs. The Competition (americanbankingnews.com)
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down $0.05 during trading hours on Monday, hitting $1.03. The company had a trading volume of 481,263 shares, compared to its average volume of 497,052. The company has a debt-to-equity ratio of 0.99, a quick ratio of 4.49 and a current ratio of 4.49. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.38.
Several equities research analysts have recently commented on RGLS shares. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Wednesday, July 12th. Chardan Capital downgraded Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Finally, Wedbush restated an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.60.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.